Use of the Average Baseline Versus the Time-Matched Baseline in Parallel Group Thorough QT/QTc Studies

REFERENCES

• Boos , D. , Hoffman , D. , Kringle , R. , Zhang , J. ( 2007 ). New confidence bounds for QT studies . Stat. Med. 26 : 3801 – 3817 .
   PubMed Web of Science ®Google Scholar
• Chambless , L. , Roeback , R. J. ( 1993 ). Methods for assessing difference between groups in change when initial measurement is subject to intra-individual variation . Stat. Med. 12 : 1213 – 1237 .
   PubMed Web of Science ®Google Scholar
• Cheng , B. , Chow , S. , Burt , D. , Cosmatos , D. ( 2008 ). Statistical assessment of QT/QTc prolongation based on maximum of correlated normal random variables . J. Biopharm. Stat. 18 ( 3 ): 494 – 501 .
   PubMed Web of Science ®Google Scholar
• Dmitrienko , A. , Smith , B. ( 2003 ). Repeated-measures models in the analysis of QT . Pharm. Stat. 2 : 175 – 190 .
   Google Scholar
• Guidance for Industry . ( 2008 ). E-14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Questions and Answers, November. Available at: http://www.fda.gov
   Google Scholar
• Hosmane , B. , Locke , C. ( 2005 ). A simulation study of power in thorough QT/QTc studies and a normal approximation for planning purposes . Drug Information J. 39 : 447 – 455 .
   Web of Science ®Google Scholar
• International Conference on Harmonization . ( 2005 ). ICH E-14. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs . Fed. Reg. 70 : 61134 – 61135 .
   PubMedGoogle Scholar
• Koch , H. J. , Raschka , C. , Banzer , W. ( 1999 ). Diurnal variation of ECG intervals and R or T amplitudes in healthy male subjects assessed by means of spectral and cosinor analysis . Jpn. Heart J. 40 ( 1 ): 45 – 53 .
   PubMedGoogle Scholar
• Pharmaceutical Manufacturers Association of America, QT Statistics Expert Team . ( 2005 ). Investigating drug-induced QT and QTc prolongation in the clinic: a review of statistical design and analysis considerations: report from the Pharmaceutical Research and Manufacturers of America QT Statistics Expert Team . Drug Information J. 39 ( 3 ): 243 – 265 .
   Google Scholar
• Senn , S. J. ( 1989a ). Covariate imbalance and random allocation in clinical trials . Stat. Med. 8 : 467 – 475 .
   PubMed Web of Science ®Google Scholar
• Senn , S. J. ( 1989b ). The use of baselines in clinical trials of bronchodilators . Stat. Med. 8 : 1339 – 1350 .
   PubMed Web of Science ®Google Scholar
• Senn , S. J. ( 2006 ). Change from baseline and analysis of covariance revisited . Stat. Med. 25 : 4334 – 4344 .
   PubMed Web of Science ®Google Scholar
• Sethuraman , V. , Sun , Q. ( 2008 ). Impact of baseline ECG collection on the planning, analysis and interpretation of ‘thorough’ QT trials . Pharm. Stat. 8 ( 2 ): 113 – 124 .
   Google Scholar
• Tian , H. , Natarajan , J. ( 2008 ). Effect of baseline measurement on the change from baseline in Qtc intervals . J. Biopharm. Stat. 18 ( 3 ): 542 – 552 .
   PubMed Web of Science ®Google Scholar
• Wei , L. , Zhang , J. ( 2001 ). Analysis of data with imbalance in the baseline outcome variable for randomized clinical trials . Drug Information J. 35 : 1201 – 1214 .
   Google Scholar
• Zhang , J. , Machado , S. G. ( 2008 ). Statistical issues including design and sample size calculation in thorough QT/QTc studies . J. Biopharm. Stat. 18 ( 3 ): 451 – 467 .
   PubMed Web of Science ®Google Scholar